The strong efficacy and safety data across difficult-to-treat AML populations (TP53-mut, complex karyotype) significantly de-risks the TUS+VEN+AZA triplet program. Monitor for next clinical milestones, potential partnership interest, and upcoming financing needs as the company advances toward pivotal trials.
Price Chart
Executive Summary
Aptose Biosciences presented updated Phase 1/2 TUSCANY trial data for tuspetinib (TUS) triplet therapy in newly diagnosed AML at the EHA 2026 Congress. The data showed an 86.2% composite complete response (CRc) rate in evaluable patients and an 86.4% MRD-negativity rate among responders, including 100% CR in TP53-mutated patients at the 160 mg dose. No financial data or guidance was provided in this clinical data update.
Key Facts
- Composite complete response (CRc) rate across all evaluable patients was 86.2% (25 of 29 patients).
- MRD-negativity rate among patients achieving CR/CRh was 86.4%.
- At the 160 mg dose (n=13), CRc rate was 76.9% (10 of 13 patients).
- 100% composite complete remission in all 4 patients with TP53-mutation with complex karyotype at the 160 mg dose.
- No treatment-related deaths or QTc prolongation, CPK elevations, or differentiation syndrome reported.
- Data presented in an oral presentation at the EHA 2026 Congress in Stockholm, Sweden.
Financial Impact
No financial figures reported; clinical-stage company with no revenue or earnings data in this filing.
Risk Factors
- Clinical-stage company with no approved products or revenue; requires additional capital to fund ongoing trials.
- Forward-looking statements caution about ability to obtain capital and continue as a going concern.
- Early-stage data (Phase 1/2, n=32) may not replicate in larger pivotal trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-004119 |
| Exhibit: exh_991.htm | 0001171843-26-004119 |
| Document: 0001171843-26-004119-index-headers.html | 0001171843-26-004119 |
| Document: 0001171843-26-004119-index.html | 0001171843-26-004119 |
| Document: 0001171843-26-004119.txt | 0001171843-26-004119 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 1, 2026 16w ago | 15-12G | $1.68 $1.69 | ▼ −0.60% | ▼ −0.64% | — |
Jun 15, 2026 19w ago | 8-K | $1.61 $1.48 | ▼ −8.07% | ▼ −5.46% | — |
May 29, 2026 21w ago | 8-K | $1.65 $1.57 | ▼ −4.85% | ▼ −2.32% | — |
May 13, 2026 23w ago | 8-K | $1.71 $1.71 | · 0.00% | ▲ +0.72% | — |
Mar 19, 2026 31w ago | 8-K | $1.62 $1.64 | ▲ +1.23% | ▲ +3.45% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers